Aridis Pharmaceuticals, Inc.

ARDS

Aridis Pharmaceuticals, Inc.

ARDS

Insider Sentiment (TTM):

Last Purchase:2024-06-24Last Sale:-Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2023-12-31Institutional Shares Owned:6Shares Outstanding:37,428,943Institutional Ownership Pct.:0.00%

Earnings Market Reaction:

Filing Date:2023-11-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30
Assets
Cash And Cash Equivalents At Carrying Value	0	0	1	5	2	6	12	18	18	4	10	8	6
Restricted Cash Current	-	-	-	0	1	1	1	1	-	-	-	-	-
Assets Current
Accounts Receivable Net Current	0	0	-	1	-	1	-	0	1	-	-	0	-
Assets Current	4	4	7	12	9	13	20	24	24	9	15	13	10
Other Receivables	0	0	0	0	0	1	0	0	0	0	0	0	0
Capitalized Contract Cost Net Current	-	-	2	2	2	2	3	2	2	2	2	2	2
Prepaid Expense And Other Assets Current	4	4	3	3	4	2	2	3	2	3	2	2	2
Property Plant And Equipment Net	1	1	1	1	1	1	1	1	1	1	1	1	1
Operating Lease Right Of Use Asset	1	1	1	1	2	2	2	2	-	-	-	-	-
Finite Lived Intangible Assets Net	0	0	0	0	0	0	0	0	0	0	0	0	0
Restricted Cash Noncurrent	1	1	1	1	1	1	1	1	1	1	1	1	-
Equity Method Investments	-	-	-	-	-	-	-	0	-	-	-	0	0
Capitalized Contract Cost Net Noncurrent	-	-	0	0	0	0	0	0	0	0	0	0	1
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0	1
Assets	7	6	9	15	12	17	24	27	26	11	18	15	12
Liabilities And Stockhold…
Accounts Payable Current	5	6	4	2	4	3	3	5	3	2	3	2	1
Accrued Liabilities Current	8	8	9	10	8	8	6	6	7	2	2	1	2
Operating Lease Liability Current	1	1	1	1	1	1	0	-	-	-	-	-	-
Liabilities Current
Contract With Customer Liability Current	0	0	19	20	20	21	21	21	20	19	19	19	15
Liabilities Current	17	20	35	37	42	31	31	33	29	24	25	22	18
Notes Payable Current	-	-	0	1	1	-	0	1	0	0	1	0	0
Other Liabilities Current	0	0	0	0	0	0	0	0	0	0	0	0	-
Contract With Customer Liability Noncurrent	-	-	1	1	1	1	1	1	1	1	1	1	5
Operating Lease Liability Noncurrent	1	1	1	1	1	2	2	-	-	-	-	-	-
Long Term Notes Payable	-	-	-	-	3	11	11	5	0	0	0	0	0
Other Liabilities Noncurrent	-	-	-	-	-	-	0	0	0	0	0	0	0
Liabilities	18	21	37	39	48	45	44	40	30	25	26	24	23
Preferred Stock Value	-	-	-	-	-	-	-	-	0	-	-	-	-
Stockholders Equity Inclu…
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	171	169	169	166	153	153	153	152	152	122	121	114	106
Accumulated Other Comprehensive Income Loss Net Of…	8	7	6	5	-	-	-	-	-	-	-	-	-
Retained Earnings Accumulated Deficit	-190	-190	-202	-196	-189	-181	-173	-165	-156	-135	-130	-123	-117
Stockholders Equity	-12	-15	-28	-24	-36	-28	-20	-13	-4	-13	-9	-9	-11
Liabilities And Stockholders Equity	7	6	9	15	12	17	24	27	26	11	18	15	12
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	60	60	60	60	60	60	60	60	60	60	60	60	60
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	100	100	100	100	100	100	100	100	100	100	100	100	100
Common Stock Shares Issued	45	36	36	27	18	18	18	18	14	11	11	10	9
Shares Outstanding	45	36	36	27	18	18	18	18	14	11	11	10	9

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2023	-21.46%	-15.00%	-43.57%	12.28%	29.82%	22.11%	8.75%	-12.37%	-5.57%	-	-	-
2022	37.74%	16.04%	111.32%	-6.37%	-50.98%	-55.88%	6.53%	38.60%	-34.90%	14.67%	44.82%	-22.80%
2021	-3.52%	19.83%	-20.16%	3.75%	-10.00%	-12.50%	-25.00%	-15.58%	-28.99%	-19.15%	-25.53%	-21.99%
2020	-	-	-	-	-	-	-2.19%	3.65%	17.96%	1.83%	3.13%	15.48%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30
Liquidity Ratios
Current Ratio	0.24	0.19	0.19	0.32	0.20	0.41	0.64	0.73	0.82	0.38	0.61	0.57	0.56
Quick Ratio	0.03	0.02	0.10	0.22	0.12	0.35	0.56	0.65	0.74	0.24	0.52	0.47	0.44
Working Capital	-13.37M	-16.51M	-28.87M	-25.27M	-33.64M	-18.42M	-11.25M	-8.96M	-5.31M	-14.74M	-9.70M	-9.69M	-7.93M
Leverage & Debt
Debt to Equity	-1.55	-1.43	-1.34	-1.61	-1.34	-1.60	-2.17	-3.04	-7.28	-1.84	-3.05	-2.74	-2.07
Interest Coverage TTM	-4.99	-36.58	-138.62	-69.91	-58.73	-88.77	-87.17	-171.53	-634.63	-363.94	-291.59	-162.33	-80.97
Debt Ratio	2.81	3.30	3.96	2.65	3.96	2.67	1.86	1.49	1.16	2.18	1.49	1.57	1.93
Efficiency & Turnover
Asset Turnover TTM	2.40	1.93	0.18	0.15	0.15	0.21	0.13	0.07	-0.02	0.00	0.05	0.05	0.09
Days Sales Outstanding TTM	6.81	9.80	-	118.08	-	122.44	-	-	-807.52	-	-	-	-
Receivables Turnover TTM	53.62	37.24	-	3.09	-	2.98	-	-	-0.45	-	-	-	-
Per Share Metrics
Diluted EPS TTM	-0.03	-0.25	-	-	-2.09	-2.81	-2.67	-3.77	-	-	-2.22	-2.44	-
Free Cash Flow Per Share TTM	-0.48	-0.59	-0.76	-1.56	-1.38	-1.63	-1.66	-1.92	-2.02	-1.97	-2.01	-2.27	-1.33
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-3.95%	-33.24%	-965.57%	-970.33%	-1,086.39%	-1,500.81%	-1,588.39%	-2,782.48%	8,845.58%	-74,993.94%	-2,274.40%	-2,240.10%	-1,113.35%
Net Profit Margin TTM	-5.11%	-41.62%	-985.30%	-982.56%	-1,288.69%	-1,666.69%	-1,733.84%	-3,017.59%	8,673.89%	-72,696.97%	-2,272.00%	-2,233.30%	-1,107.90%
Growth Metrics
Net Revenue Growth (1Y)	680.42%	649.45%	9.70%	101.37%	-733.85%	8,933.33%	172.20%	53.50%	-122.60%	-96.70%	-	-2.15%	-26.87%
Net Income Growth (1Y)	-96.91%	-81.29%	-37.66%	-34.43%	-5.83%	107.10%	107.72%	107.41%	76.94%	0.13%	-19.21%	-24.76%	-39.80%
EPS Growth (1Y)	-98.54%	-90.82%	-63.72%	-57.08%	-33.74%	31.43%	20.05%	54.71%	26.78%	-20.46%	-29.53%	-26.81%	-41.34%
Valuation Metrics
P/E TTM	-3.35	-0.85	-0.32	-0.73	-0.45	-0.39	-0.66	-0.62	-1.17	-3.47	-2.66	-2.49	-2.85
P/B TTM	-0.32	-0.53	-0.34	-0.91	-0.46	-0.70	-1.53	-2.18	-11.03	-6.16	-7.06	-6.41	-5.59
P/S TTM	0.17	0.36	3.20	7.17	5.75	6.53	11.45	18.66	-101.40	2,519.04	60.36	55.65	31.59
Market Cap	3.82M	7.93M	9.55M	22.16M	16.46M	19.47M	31.15M	28.64M	45.83M	83.13M	60.36M	55.65M	63.18M
Enterprise Value	3.29M	7.41M	7.94M	17.12M	17.66M	22.44M	27.70M	14.63M	27.11M	79.04M	50.10M	47.64M	57.68M
Calculated Values
Free Cash Flow TTM	-17.93M	-21.22M	-23.02M	-29.21M	-24.38M	-28.82M	-29.40M	-23.55M	-25.21M	-22.10M	-20.60M	-20.84M	-11.87M
Net Debt	-535.00K	-519.00K	-1.61M	-5.04M	1.20M	2.97M	-3.46M	-14.01M	-18.72M	-4.09M	-10.26M	-8.02M	-5.50M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2024-06-24Purchase

Owner: Patzer, Eric

Title: -

Shares: 714,286

Price/Share: $0.07

Value: $50,000.02

Shares Owned: 884,600

Relationship: Director

Ownership: Direct

2024-06-24Purchase

Owner: Truong, Vu

Title: CEO

Shares: 714,286

Price/Share: $0.07

Value: $50,000.02

Shares Owned: 1,378,639

Relationship: Director,Officer

Ownership: Direct

2021-09-07Purchase

Owner: Jafri, Hasan

Title: Chief Medical Officer

Shares: 2,091

Price/Share: $4.06

Value: $8,489.46

Shares Owned: 5,100

Relationship: Officer

Ownership: Direct

2021-07-27Purchase

Owner: Patzer, Eric

Title: -

Shares: 5,175

Price/Share: $4.84

Value: $25,047.00

Shares Owned: 702,132

Relationship: Director

Ownership: Direct

2021-07-27Purchase

Owner: Truong, Vu

Title: CEO

Shares: 5,000

Price/Share: $5.11

Value: $25,550.00

Shares Owned: 737,353

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2024-06-24	Patzer, Eric	Director	-	Direct	Purchase	714,286	0.07	$50,000.02	884,600	4
2024-06-24	Truong, Vu	Director,Officer	CEO	Direct	Purchase	714,286	0.07	$50,000.02	1,378,639	4
2021-09-07	Jafri, Hasan	Officer	Chief Medical Officer	Direct	Purchase	2,091	4.06	$8,489.46	5,100	4
2021-07-27	Patzer, Eric	Director	-	Direct	Purchase	5,175	4.84	$25,047.00	702,132	4
2021-07-27	Truong, Vu	Director,Officer	CEO	Direct	Purchase	5,000	5.11	$25,550.00	737,353	4
2021-07-27	Hamilton, John F	Director	-	Direct	Purchase	2,000	4.87	$9,740.00	2,000	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2023-12-31

0.00%

Inst. Shares: 6

Shares Outstanding: 37,428,943

2023-09-30

0.04%

Inst. Shares: 14,077

Shares Outstanding: 37,428,943

2023-06-30

2.95%

Inst. Shares: 1,066,037

Shares Outstanding: 36,077,532

2023-03-31

11.43%

Inst. Shares: 3,477,248

Shares Outstanding: 30,414,865

2022-12-31

16.80%

Inst. Shares: 3,154,978

Shares Outstanding: 18,777,335

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2023-12-31	6	37,428,943	0.00%
2023-09-30	14,077	37,428,943	0.04%
2023-06-30	1,066,037	36,077,532	2.95%
2023-03-31	3,477,248	30,414,865	11.43%
2022-12-31	3,154,978	18,777,335	16.80%
2022-09-30	1,926,355	17,701,592	10.88%
2022-06-30	1,868,621	17,701,592	10.56%
2022-03-31	1,921,951	17,701,592	10.86%
2021-12-31	1,269,355	12,291,600	10.33%
2021-09-30	1,991,144	12,454,119	15.99%
2021-06-30	1,076,775	11,233,572	9.59%
2021-03-31	1,011,836	10,230,043	9.89%
2020-12-31	740,963	9,168,744	8.08%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Aridis Pharmaceuticals, Inc. (ARDS) — SEC Financial Statements & Analysis

Aridis Pharmaceuticals, Inc. (ARDS) is a pharmaceutical preparations company, incorporated in DE. Aridis Pharmaceuticals, Inc. trades on OTC as: ARDS. Based on its latest SEC filing (Form 10-Q, period ending 2023-09-30), Aridis Pharmaceuticals, Inc. reported a 680.42% year-over-year revenue growth, a Debt-to-Equity ratio of -1.55x, a Price-to-Sales (P/S) ratio of 0.17x (TTM), a Price-to-Book (P/B) ratio of -0.32x (TTM), at a market cap of $3.82M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 680.42%
Debt To Equity: -1.55x
P/S TTM: 0.17x
P/B TTM: -0.32x
Market Cap: $3.82M

Data as of 2023-09-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Aridis Pharmaceuticals, Inc. in?

Aridis Pharmaceuticals, Inc. (ARDS) operates in the Pharmaceutical Preparations industry.

What is ARDS's market cap?

Aridis Pharmaceuticals, Inc. (ARDS) has a market capitalization of $3.82M as of 2023-09-30.

What exchange does ARDS trade on?

Aridis Pharmaceuticals, Inc. (ARDS) trades on the OTC.

Where is Aridis Pharmaceuticals, Inc. incorporated?

Aridis Pharmaceuticals, Inc. is incorporated in DE.